Healthcare Industry News: MRI-guided
News Release - March 13, 2012
ViewRay Closes Round of Series C FinancingLeading Venture Capital Firms Invest $45 Million to Accelerate Development of ViewRay's Propriety MRI-guided Radiation Therapy System
CLEVELAND, March 13, 2012 -- (Healthcare Sales & Marketing Network) -- ViewRay™ Incorporated, a privately held medical device company, has closed the final tranche of a $45 million round of Series C venture capital financing. Institutional investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital (SVC) GmbH.
The ViewRay system is designed as the first comprehensive image-guided radiation therapy system, providing a patented combination of simultaneous radiotherapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer. ViewRay's treatment planning and delivery software received 510(k) premarket notification clearance from the U.S. FDA in 2011, and its integrated imaging and radiotherapy delivery system is now pending 510(k) review.
"Thanks to the ongoing commitment of our investors, ViewRay is in the process of preparing for market launch," said ViewRay President and CEO Gregory M. Ayers, MD, PhD. "With our continued and substantial progress, our investors are even more enthusiastic about the potential of ViewRay and the promise of MRI-guided radiotherapy."
The first ViewRay research system is undergoing final installation at the Siteman Cancer Center at Barnes‐Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri. Additional ViewRay research partners include the University of Wisconsin Carbone Cancer Center and the University of California, Los Angeles, Health System and Jonsson Comprehensive Cancer Center.
ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The ViewRay system is being designed to provide continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians will be able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit http://www.viewray.com.
ViewRay is a trademark of ViewRay Incorporated.
ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.